Increasing Naloxone Distribution in VT Emergency Departments by Harris, Olivia M.
University of Vermont
ScholarWorks @ UVM
Family Medicine Clerkship Student Projects College of Medicine
2016
Increasing Naloxone Distribution in VT
Emergency Departments
Olivia M. Harris
UVM College of Medicine
Follow this and additional works at: http://scholarworks.uvm.edu/fmclerk
Part of the Medical Education Commons, and the Primary Care Commons
This Book is brought to you for free and open access by the College of Medicine at ScholarWorks @ UVM. It has been accepted for inclusion in Family
Medicine Clerkship Student Projects by an authorized administrator of ScholarWorks @ UVM. For more information, please contact
donna.omalley@uvm.edu.
Recommended Citation
Harris, Olivia M., "Increasing Naloxone Distribution in VT Emergency Departments" (2016). Family Medicine Clerkship Student
Projects. Book 123.
http://scholarworks.uvm.edu/fmclerk/123
Increasing Naloxone Distribution 
in VT Emergency Departments
Stowe Family Practice
Olivia Harris
Family Medicine (12.14.2014 – 1.22.2015)
Mentor: Dr. Katherine Marvin MD
The Problem:
• Drug overdose was the leading cause of  injury 
death in 2013 (CDC)
• Deaths involving opioids have risen dramatically 
over the last 5 years in Vermont
• Deaths from heroin doubled from 2012 to 2013 1
• 50+ Vermonters die from opioid overdose each year 1
• Preliminary data shows that between January-
September of  2015, there were already 55 deaths 
involving an opioid in VT 1
The Problem:
• It is critical that physicians be aware of, and address this problem:
• “Approximately two-thirds of  individuals with addiction will see a primary care or urgent care 
physician every six months, and many others are regularly examined by other medical specialists.” 2
• Despite the availability of  Naloxone (Narcan), an opioid receptor antagonist which effectively 
and safely reverses the detrimental effects of  opioids, Emergency Department physicians in 
Vermont are not distributing Naloxone kits to all overdose patients
• Physician apprehension to prescribing Naloxone involves:
• lack of  awareness 3, 
• negative attitudes towards drug users 3, 
• belief  that distributing Naloxone will increase drug use 3, and 
• fear of  liability
A price to pay
• “Drug misuse and abuse caused about 2.5 million emergency 
department (ED) visits in 2011.” 4
• “Among those ED visits, 420,040 visits were related to opioid 
analgesics.” 4
• “In the United States, prescription opioid abuse costs were about $55.7 
billion in 2007. Of  this amount, 46% was attributable to workplace costs 
(e.g., lost productivity), 45% to healthcare costs (e.g., abuse treatment), 
and 9% to criminal justice costs.” 4
Community Perspective
Brief  interviews were conducted with two ED physicians, and with participants 
at a VT Medically Assisted Treatment (MAT) learning collaborative:
• An ED physician from Copley Hospital in Stowe, VT endorses a commonly held 
belief  that prescribing Naloxone to patients with overdose in the ED enables them 
to continue using, and to use more opioids
• Conversely, a physician from Treatment Associates states that,
• “Anyone who is not participating in the Narcan movement is a victim of  bias against 
those with the disease of  addiction. Addiction should be treated the same as any other 
disease, like hypertension or diabetes.”
Community Perspective
• A physician working in UVMMC Emergency Department agrees that Naloxone kits need to 
be distributed to any patient who comes to the ED with an overdose. When asked about why 
this is not occurring, Dr. Clauss responded that some physicians may not be aware of  this 
option, some of  these patients leave prematurely before the kit can be provided, and that 
many patients are given information about where they can get free Naloxone kits in the 
community
• However, an RN involved in the MAT at Stowe Family 
Practice, feels that Naloxone kits need to be provided at 
the time of  the ED visit rather than redirecting patients 
to community resources due to the unreliability of  this 
patient population, lack of  transportation, and lack of  
accessible community resources in many areas of  
Vermont
Methodology & Intervention
• Methodology:
• A literature review was performed to explore:
• attitudes of  physicians regarding Naloxone prescription, and to assess the validity of  
commonly held beliefs among this population
• The effectiveness of  distributing Naloxone kits to patients with opioid overdose in regard to 
prevention of  future overdose, safety, and cost-effectiveness
• Investigation of  whether physicians at the UVMMC Emergency Department are 
prescribing Naloxone kits
• Sought help in performing a PRISM search to assess how many patients were treated for an 
overdose in the last 6 months
• Contacted a pharmacist at UVMMC to collect data on the number of  kits prescribed 
• Intervention:
• After compiling the data found in the literature review, an informational pamphlet was developed 
to be distributed among emergency department physicians with the hope of  increasing awareness 
and ultimately increasing the distribution of  Naloxone kits in this setting
Results & Response Data
• Evidence in the literature shows that:
• Overdose deaths are significantly reduced in areas where Naloxone distribution programs 
have been implemented 5
• Providing Naloxone “does not encourage opiate users to increase their drug consumption, 
nor does it increase the likelihood that they will harm themselves or those around them.” 3
• Participation in Naloxone distribution programs reduces the use of  opioids and increases 
users' desire to seek addiction treatment. 6
• Naloxone has no psychoactive effects or potential for abuse, and studies have indicated 
“extremely low rates of  adverse events in numerous pilot studies of  distribution” 6
• In addition, legal changes have been made to protect physicians who prescribe 
Naloxone, described in Act 75 in Vermont (http://www.vtmd.org/act-75-
prescription-drug-abuse-prevention-and-monitoring-implementation-timeline)
Results and Response Data 
• A basic PRISM search using “heroin overdose” and “opiate overdose” as 
discharge diagnoses showed 43 patients between 6/1/2015 – 11/30/2015
• UVMMC Pharmacy distributed 17 Naloxone kits during this same time 
period
Evaluation of  Effectiveness & Limitations
• Evaluating effectiveness:
• Another PRISM search with an accompanying evaluation of  the number of  Naloxone 
kits distributed at UVMMC should be performed 6 months following the distribution 
of  the information packets to determine whether the number of  kits more closely 
matches the number of  patients treated for an opioid overdose
• Limitations of  this project include:
• Short period of  time within which to complete the project
• Difficulty capturing the real number of  patients treated for overdose at UVMMC due 
to variation in discharge diagnoses used 
Future Projects
• Future projects may aim to:
• Gain a better understanding of  physicians’ attitudes in Vermont Emergency 
Departments regarding the prescription of  Naloxone kits through personal interviews, 
survey’s/questionnaires, etc.
• Develop a separate information pamphlet for patients regarding the safety and efficacy 
of  Naloxone kits in preventing overdose fatalities from opiates
• Broaden the distribution of  information packets to include primary care physicians as 
well as other emergency departments in Vermont
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